Nanoscope Therapeutics Awarded ‘Best of Show’ for Retina at Eyecelerator@AAO 2023

Nanoscope Therapeutics Awarded ‘Best of Show’ for Retina at Eyecelerator@AAO 2023

DALLAS, TX (November 3, 2020) — Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases and age-related macular degenerations (AMD), has been awarded “Best of Show for Retina” at Eyecelerator@AAO2023. The award was presented to Nanoscope’s Chief Medical Officer, Samuel Barone, MD, for his presentation during the event’s Retina Showcase.  In his presentation Dr. Barone showcased the company’s Multi-Characteristic Opsin platform and its potential to restore vision based on recent clinical data in patients with advanced retinal degenerative diseases.

Sam Barone, MD, Chief Medical Officer of Nanoscope Therapeutics accepts the “Best of Show – Retina” award during Eyecelerator@AAO2023 in San Francisco, November 2, 2023

Recipient of the Best of Show Award is chosen by a vote of conference attendees. “We are thrilled and honored for this recognition,” said Sulagna Bhattacharya, CEO, “It is very special because it comes from our own retina community. We thank you all for the encouragement. It means a great deal to our entire team.”

“The patient experience was front and center in my presentation, and I appreciate the acknowledgment of our work to make a difference in their lives,” said Samuel Barone, CMO.

Nanoscope Therapeutics leadership celebrates “Best of Show” award at Eyecelerator. From left, Jared Stephens, VP Strategy & Business; Samarendra Mohanty, Co-Founder & President; Sam Barone, Chief Medical Officer; Sulagna Bhattacharya, CEO; Michael Marquez, CFO.

Eyecelerator@AAO2023 took place on November 2, 2023 in advance of the American Academy of Ophthalmology Annual Meeting in San Francisco.  Eyecelerator focuses on emerging trends, advancements and innovations in eyecare.

About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing gene-agnostic, sight-restoring optogenetic therapies for the millions of patients blinded by inherited retinal diseases, for which no cure exists. The company’s lead asset, MCO-010, recently reported topline results from the RESTORE Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trial in the U.S. for retinitis pigmentosa (NCT04945772). The company has also recently completed their end-of-study visit for the Phase 2 STARLIGHT trial of MCO-010 therapy in Stargardt patients (NCT05417126). MCO-010 has received FDA fast track designations and FDA orphan drug designations for both retinitis pigmentosa and Stargardt. Preclinical assets include non-viral laser-delivered MCO-020 gene therapy for geographic atrophy.

 

Investor Contact:
Argot Partners
212-600-1902
PR@nanostherapeutics.com

SOURCE Nanoscope Therapeutics

On November 3, 2023   /   Nanoscope Press Release, Home Page  
Nanoscope Therapeutics, Inc.
Trinity Towers
2777 N. Stemmons Fwy.
Dallas, TX 75207
(817) 857-1186

  • Dr. Samarendra Mohanty, PhD |  Co-Founder & President

    Samarendra Mohanty (Co-Founder/President) is an inventor & serial entrepreneur with 20+ years experience in Biomedical Sciences. He is Co-Founder of several Biotechs and Biomedical device /diagnostic companies (developed & commercialized $100K+ biomedical instruments.)

    Samar obtained M.Tech in Applied Optics from the Indian Institute of Technology-Delhi and a PhD in (Bio)Physics from the Indian Institute of Sciences-Bangalore.

    His extensive Biomedical Technologies experience includes serving as Professor/Senior Scientist at the University of Texas;  University of California, Irvine; Center for Adv. Tech (India); Int. Mol. Biotech (Germany); Univ. Pavia (Italy); NUS (Singapore); and University of St. Andrews (UK). He has authored over 200 international patents and publications in leading journals including Nature and Nature Photonics.

    He is the Principal Investigator for major grants from the National Eye Institute including Audacious Goal Initiative and Bioengineering Research grants. He serves on the editorial board of journals and chairs an international conference on optogenetics. He is the winner of a 2019 Healthcare Heroes award (Fort Worth Business Press), Retinal Organoid Challenge Award, Audacious Goal Initiative Award (NIH), Finalist of Tech Titan, and NIH-Director’s Innovator Award.